A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

NCT05592990 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Achilles Tendinopathy

Interventions

DRUG: NGI226
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals